LifeScience Biologics
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...
March 19, 2026 | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
March 19, 2026 | News
DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, announced it has signed distribution ag...
March 19, 2026 | News
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and ...
March 18, 2026 | News
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...
March 19, 2026 | News
-Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammat...
March 18, 2026 | News
Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry,...
March 18, 2026 | News
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease...
March 18, 2026 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...
March 17, 2026 | News
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special...
March 16, 2026 | News
Most Read
Bio Jobs
News